Russell Investments Group Ltd. Lowers Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Russell Investments Group Ltd. cut its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 75.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,548 shares of the company's stock after selling 154,125 shares during the period. Russell Investments Group Ltd. owned about 0.06% of Progyny worth $872,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Progyny by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock valued at $149,939,000 after purchasing an additional 48,271 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after buying an additional 1,183,558 shares during the last quarter. River Road Asset Management LLC bought a new position in Progyny in the fourth quarter worth approximately $25,529,000. Fort Washington Investment Advisors Inc. OH lifted its holdings in Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after purchasing an additional 695,740 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its holdings in Progyny by 52.2% in the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock worth $22,989,000 after buying an additional 456,853 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Down 0.6 %

PGNY stock traded down $0.14 during midday trading on Friday, hitting $22.76. The company's stock had a trading volume of 530,308 shares, compared to its average volume of 1,743,497. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 2.39 and a beta of 1.33. The stock's 50-day moving average price is $21.94 and its 200 day moving average price is $19.05. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $33.84.

Analysts Set New Price Targets

PGNY has been the subject of several recent research reports. Bank of America lifted their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group raised their target price on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, February 28th. Finally, BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $23.64.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.